NADK and neoplasm: Importantly, this sharp increase in ROS on NADK depletion corresponded with a negative impact on AsPC-1 xenograft tumour growth (Fig. 5e; P value=0.0003, t-test, averaged across three shRNAs versus NT), suggesting that elevated levels of ROS may be inhibitory to PDAC growth as reported previously (ref. 24 and reviewed in ref. 25).